Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test
Background: Cell and gene therapies have the potential to provide therapeutic breakthroughs, but the high costs of researching, developing, manufacturing and delivering them translate into prices that may challenge healthcare budgets. Various measures exist that aim to address the affordability chal...
Saved in:
| Main Authors: | Jesper Jørgensen, Panos Kefalas |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2017-01-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20016689.2017.1355203 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate
by: Jesper Jørgensen, et al.
Published: (2019-01-01) -
Towards implementing new payment models for the reimbursement of high-cost, curative therapies in Europe: insights from semi-structured interviews
by: Thomas Desmet, et al.
Published: (2025-01-01) -
The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease
by: Jesper Jørgensen, et al.
Published: (2018-01-01) -
Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy
by: Panos Kefalas, et al.
Published: (2018-01-01) -
Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries
by: Jesper Jørgensen, et al.
Published: (2020-01-01)